First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed metastatic (stage IV) NSCLC * Measurable disease according to RECIST v.1.0 2009 * KRAS, BRAF and PI3K wild type in primary tumor or metastatic tissue. * Age ≥18 * PS \< 2 * Adequate organ function Haematology: * Neutrophil count ≥1.5x10\^9/L * Platelet count ≥100x10\^9/L * Leucocyte count \> 3,000/mm Hepatic function: * Total bilirubin ≤ 1.5 times the upper normal limit (UNL) * Serum transaminases ≤ 2.5xUNL in absence of liver metastases, or ≤ 5xUNL in presence of liver metastases Renal Function: * Creatinine clearance ≥ 50 mL/min and serum creatinine ≤ 1.5xUNL Metabolic function: * Magnesium ≥ lower limit of normal. * Calcium ≥ lower limit of normal. Consent to translational research studies Written informed consent Exclusion Criteria: * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment/randomization, active severe infections or other concurrent disease. * Known CNS metastasis (pretreatment routine assessment not required) * Prior chemotherapy for metastatic disease * Indication for radiation therapy or prior radiotherapy within 30 days before treatment start. * Other malignant diseases within 5 years prior to inclusion in the study, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ. * Other experimental therapy within 30 days prior to treatment initiation. * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. * Patients pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. * Patients (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.